IOL Chemicals and Pharmaceuticals reported results for fourth quarter (Q4) and year ended March 31, 2023.
The company has reported 2- fold jump in its net profit at Rs 65.27 crore for the quarter under review as compared to Rs 27.75 crore for the same quarter in the previous year. Total income of the company increased by 2.85% at Rs 595.93 crore for Q4FY23 as compared to Rs 579.42 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 2- fold jump in its net profit at Rs 64.78 crore for fourth quarter ended March 31, 2023 as compared to Rs 29.76 crore for the same quarter in the previous year. Total income of the company marginally increased by 2.85% at Rs 595.94 crore for Q4FY23 as compared to Rs 579.42 crore for the corresponding quarter previous year.
For the year ended March 31, 2023, the company has reported 15.50% fall in its net profit at Rs 139.98 crore as compared to Rs 165.66 crore for the previous year. However, total income of the company marginally increased by 1.20% at Rs 2,242.68 crore for year under review as compared to Rs 2,216.06 crore for year ended March 31, 2022.
For the year ended March 31, 2023, on the consolidated basis, the company has reported 17.02% fall in its net profit at Rs 139.14 crore as compared to Rs 167.67 crore for the previous year. However, total income of the company increased by 1.20% at Rs 2242.72 crore for year under review as compared to Rs 2216.06 crore for year ended March 31, 2022.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1529.55 |
Dr. Reddys Lab | 6315.00 |
Cipla | 1423.40 |
Zydus Lifesciences | 1021.00 |
Lupin | 1679.75 |
View more.. |